CDC/ACIP [to 2 December 2017]

 
CDC/ACIP [to 2 December 2017]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Wednesday, November 29, 2017
Vital Signs Teleconference: HIV Testing Frequency – Transcript

Frequency of HIV Testing and Time from Infection to Diagnosis Improves – Digital Press Kit Tuesday, November 28, 2017

Frequency of HIV Testing and Time from Infection to Diagnosis Improve – Press Release Tuesday, November 28, 2017

MMWR News Synopsis for November 30, 2017
Scale-Up of Voluntary Medical Male Circumcision Services for HIV Prevention – 12 Countries in Southern and Eastern Africa, 2013 – 2016
A substantial increase in voluntary medical male circumcision (VMMC) through CDC-supported programs is helping to prevent the spread of HIV in the world’s most heavily affected countries. The latest data show that meeting the global target of 27 million circumcisions by 2021 will require redoubling current efforts and developing new strategies to increase the number of men seeking circumcisions. New data show that a substantial increase in voluntary medical male circumcision (VMMC) through CDC-supported programs is helping to prevent the spread of HIV in the world’s most heavily affected countries – and that more needs to be done. The number of circumcisions supported by CDC has increased from over 1 million in nine countries during 2010–2012 to nearly 5 million during 2013–2016 in 12 Southern and Eastern African countries. VMMC reduces a man’s risk of heterosexually acquired HIV by 60 percent. As a key agency for the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), CDC supports VMMC in 12 Eastern and Southern African countries with high HIV prevalence and low male circumcision rates. While millions of men have successfully accessed this prevention intervention, the number of VMMCs decreased during 2016.

Fractional-Dose Inactivated Poliovirus Vaccine Campaign – Sindh Province, Pakistan, 2016
Countries should weigh the potential benefits of using fractional-dose intradermal inactivated polio vaccine (fIPV) against the operational challenges associated with its use. In response to isolation of type 2 vaccine derived poliovirus (VDPV2) from sewage samples taken from Hyderabad, Pakistan,  fIPV was used in a polio vaccination campaign targeting children ages 4-23 months. The vaccine coverage rate during the campaign was relatively high; however, operational challenges related to the use of an intradermally injected vaccine were encountered during the campaign. Countries that decide to use fIPV should undertake meticulous planning and preparation to address operational challenges and to ensure judicious use of fIPV due to the limited global stock of IPV.